RESULTS	The key determinants of cost effectiveness were : the effectiveness of fluvastatin in reducing acute myocardial infarction , subsequent PCI , coronary artery bypass graft and cardiac deaths ; the utility weight associated with a subsequent post-PCI state ; the cost of fluvastatin ; and the time horizon evaluated .\